Second study will assess sarilumab for Covid-19

The Phase II/III trial will evaluate the IL-6 inhibitor in the treatment of Covid-19 patients in Italy, Spain, Germany, France, Japan, Canada and Russia. This is the second trial of its kind, following anecdotal reports that tocilizumab showed efficacy in treating these patients.


Biospace Inc.